Curocell Secures Regulatory Approval to Amend Phase 1/2 Clinical Trials for Leukemia Drug

MT Newswires Live11-18 19:21

Curocell (KOSDAQ:A372320) secured regulatory approval from the South Korean Ministry of Food and Drug Safety to amend the Phase 1 clinical trials to evaluate the tolerability, safety, and efficacy of its CRC01 drug candidate, according to a Wednesday filing with the Korea Exchange.

The drug candidate is used in patients with relapsed or refractory adult B-cell acute lymphoblastic leukemia, while the Phase 2 trials will evaluate the efficacy and safety of CRC01 as assessed by independent evaluation.

The amendment will help separate the clinical trial protocols for independent and efficient operation of the acute lymphoblastic leukemia clinical trial.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment